Published in Proc Natl Acad Sci U S A on February 05, 2009
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst (2010) 4.80
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One (2010) 3.96
A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet (2012) 3.20
MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res (2010) 2.48
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst (2011) 1.92
SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One (2013) 1.74
Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res (2011) 1.59
Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol (2010) 1.53
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res (2013) 1.46
Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer. Nat Commun (2016) 1.39
Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput Biol (2012) 1.32
Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol (2011) 1.32
Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction. PLoS One (2010) 1.17
Systematic evaluation of medium-throughput mRNA abundance platforms. RNA (2012) 1.15
Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma. Oncotarget (2016) 1.06
A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS One (2011) 1.05
Toward better benchmarking: challenge-based methods assessment in cancer genomics. Genome Biol (2014) 1.05
Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. Genome Med (2013) 1.05
Can survival prediction be improved by merging gene expression data sets? PLoS One (2009) 1.04
A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One (2009) 1.03
Principal component analysis-based filtering improves detection for Affymetrix gene expression arrays. Nucleic Acids Res (2011) 0.98
Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One (2011) 0.98
Improving accuracy for cancer classification with a new algorithm for genes selection. BMC Bioinformatics (2012) 0.95
Identification of a clinically relevant androgen-dependent gene signature in prostate cancer. Cancer Res (2011) 0.94
The role of gene expression profiling in early-stage non-small cell lung cancer. J Thorac Dis (2010) 0.93
FISH as an effective diagnostic tool for the management of challenging melanocytic lesions. Diagn Pathol (2011) 0.92
A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med (2014) 0.92
Growth of lung cancer cells in three-dimensional microenvironments reveals key features of tumor malignancy. Integr Biol (Camb) (2011) 0.91
Prognostic markers in lung cancer: is it ready for prime time? Transl Lung Cancer Res (2014) 0.90
MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res (2015) 0.90
Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis (2012) 0.89
Inferring the functions of longevity genes with modular subnetwork biomarkers of Caenorhabditis elegans aging. Genome Biol (2010) 0.89
Translating metastasis-related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol (2013) 0.88
NOTCH1, HIF1A and other cancer-related proteins in lung tissue from uranium miners--variation by occupational exposure and subtype of lung cancer. PLoS One (2012) 0.86
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One (2013) 0.85
Algebraic comparison of partial lists in bioinformatics. PLoS One (2012) 0.85
Integrative computational biology for cancer research. Hum Genet (2011) 0.85
Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol (2012) 0.85
The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev (2014) 0.84
Ensemble of gene signatures identifies novel biomarkers in colorectal cancer activated through PPARγ and TNFα signaling. PLoS One (2013) 0.84
Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today (2015) 0.84
Predictive integration of gene functional similarity and co-expression defines treatment response of endothelial progenitor cells. BMC Syst Biol (2011) 0.82
Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer? Transl Lung Cancer Res (2013) 0.82
Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med (2012) 0.82
Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget (2015) 0.81
LTR: Linear Cross-Platform Integration of Microarray Data. Cancer Inform (2010) 0.81
EgoNet: identification of human disease ego-network modules. BMC Genomics (2014) 0.81
Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study. BMC Cancer (2010) 0.81
The path to routine use of genomic biomarkers in the cancer clinic. Genome Res (2015) 0.81
YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer (2015) 0.80
Modelling p-value distributions to improve theme-driven survival analysis of cancer transcriptome datasets. BMC Bioinformatics (2010) 0.80
Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. Am J Respir Crit Care Med (2014) 0.80
Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. Mol Oncol (2014) 0.79
Cancer computational biology. BMC Bioinformatics (2011) 0.79
The complexity of microRNAs in human cancer. J Radiat Res (2016) 0.79
Pathway-Based Genomics Prediction using Generalized Elastic Net. PLoS Comput Biol (2016) 0.78
Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res (2014) 0.78
Comparative network analysis via differential graphlet communities. Proteomics (2014) 0.78
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas. PLoS One (2015) 0.77
Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences. BMC Bioinformatics (2014) 0.77
mRNA levels in control rat liver display strain-specific, hereditary, and AHR-dependent components. PLoS One (2011) 0.77
How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol (2011) 0.77
Metagenes associated with survival in non-small cell lung cancer. Cancer Inform (2011) 0.77
Lung Cancer Gene Signatures and Clinical Perspectives. Microarrays (Basel) (2013) 0.75
Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst (2016) 0.75
Biomarkers and subtypes of cancer. Aging (Albany NY) (2015) 0.75
Sparse principal component analysis in cancer research. Transl Cancer Res (2014) 0.75
Prognostic factors in resected lung carcinomas. EJC Suppl (2013) 0.75
Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation. Oncotarget (2017) 0.75
A 25-gene classifier predicts overall survival in resectable pancreatic cancer. BMC Med (2017) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Revisions in the International System for Staging Lung Cancer. Chest (1997) 15.68
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med (2007) 10.47
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst (2003) 9.68
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med (2004) 6.36
Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A (2006) 6.26
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med (2006) 3.37
The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res (2006) 2.50
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10
Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res (2007) 1.80
Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol (2008) 1.72
Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res (2006) 1.65
Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis (2006) 1.53
The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg (2007) 1.51
Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia (2005) 1.14
Staging classification of lung cancer. A critical evaluation. Clin Chest Med (2002) 1.07
Adjuvant therapy for stage II colon cancer: an elephant in the living room? Ann Oncol (2004) 1.00
A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer (2004) 0.96
Adjuvant therapy of stage II and III colon cancer. Semin Oncol (2005) 0.94
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
International network of cancer genome projects. Nature (2010) 20.35
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med (2005) 13.01
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Reflecting on 25 years with MYC. Nat Rev Cancer (2008) 7.44
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Online predicted human interaction database. Bioinformatics (2005) 6.83
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
High-throughput mapping of a dynamic signaling network in mammalian cells. Science (2005) 5.21
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol (2014) 4.31
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol (2009) 4.27
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science (2011) 3.89
The myc oncogene: MarvelouslY Complex. Adv Cancer Res (2002) 3.68
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res (2002) 3.68
Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys (2013) 3.56
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med (2012) 3.52
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2006) 3.52
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 3.51
Non-small-cell lung cancer. Lancet (2011) 3.45
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med (2004) 3.21
Protein interaction data curation: the International Molecular Exchange (IMEx) consortium. Nat Methods (2012) 3.17
DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell (2005) 3.12
Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J (2005) 3.11
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res (2010) 2.79
Evaluation of linguistic features useful in extraction of interactions from PubMed; application to annotating known, high-throughput and predicted interactions in I2D. Bioinformatics (2009) 2.78
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol (2005) 2.76
Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol (2009) 2.74
Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog (2011) 2.74
The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.71
The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res (2006) 2.50
Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol (2003) 2.47
Unequal evolutionary conservation of human protein interactions in interologous networks. Genome Biol (2007) 2.45
Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest (2009) 2.43
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
NAViGaTOR: Network Analysis, Visualization and Graphing Toronto. Bioinformatics (2009) 2.34
K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer (2006) 2.29
The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol (2009) 2.29
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med (2009) 2.23
Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol (2008) 2.20
mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol (2011) 2.20
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol (2007) 2.10
Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol (2009) 2.08
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.03
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet (2009) 2.00
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab (2005) 1.98